Home8QQ • FRA
add
AbCellera Biologics Inc
Previous close
€2.90
Day range
€2.68 - €2.85
Year range
€2.16 - €5.15
Market cap
874.28M USD
Avg Volume
595.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 6.51M | -1.39% |
Operating expense | 59.20M | 151.15% |
Net income | -51.11M | -78.63% |
Net profit margin | -785.42 | -81.16% |
Earnings per share | -0.17 | -70.00% |
EBITDA | -56.74M | -15.44% |
Effective tax rate | 18.40% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 643.14M | -18.16% |
Total assets | 1.39B | -7.89% |
Total liabilities | 314.73M | -4.46% |
Total equity | 1.08B | — |
Shares outstanding | 295.37M | — |
Price to book | 0.79 | — |
Return on assets | -16.69% | — |
Return on capital | -20.08% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -51.11M | -78.63% |
Cash from operations | -28.88M | -27,147.17% |
Cash from investing | 3.70M | 128.92% |
Cash from financing | 3.14M | -52.56% |
Net change in cash | -21.67M | -195.86% |
Free cash flow | -10.48M | 72.64% |
About
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Founded
2012
Headquarters
Website
Employees
586
